Hudson Value Partners’s AbbVie ABBV Stock Holding History

Hudson Value Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,012	Closed	-$212K	–	110
2025 Q1	$212K	Buy	+1,012	New	+$197K	0.08%	95

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Hudson Value Partners's ABBV Position: Q2 2025 in Review

Hudson Value Partners sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 1,012 shares — an estimated $212K sold.

Hudson Value Partners first reported a position in ABBV in Q1 2025 and held it in 1 quarter. The position peaked at $212K in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Hudson Value Partners reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
Hudson Value Partners sold 1,012 AbbVie shares in Q2 2025, an estimated $212K.
Hudson Value Partners first reported a position in AbbVie in Q1 2025 and held it in 1 quarter.
Hudson Value Partners's AbbVie position peaked at $212K in Q1 2025.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Hudson Value Partners's 13F filing for Q2 2025, filed 18 Jul 2025.